Tiziana Life Sciences (TLSA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tiziana Life Sciences has received FDA Fast Track designation for its intranasal foralumab, aiming to treat Secondary Progressive Multiple Sclerosis (SPMS) and potentially other neurodegenerative diseases. The designation will expedite the review process and enhance the company’s interaction with the FDA, highlighting foralumab’s potential to meet an unmet medical need. Additionally, Tiziana is addressing Nasdaq compliance issues to prevent the delisting of its shares.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- ‘The Big Vote Coming’: Daniel Ives Weighs In on Tesla Stock as Shareholders Decide Musk’s $1 Trillion Pay Package
- ‘Time to Get Off This Train,’ Says Top Analyst About Rigetti Computing Stock Ahead of Earnings
- AMD Stock Heads Into Tuesday’s Earnings With Momentum — Here’s What This Top Investor Expects